Spots Global Cancer Trial Database for vinflunine
Every month we try and update this database with for vinflunine cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) | NCT03474107 | Ureteral Cancer Urothelial Canc... Bladder Cancer | Enfortumab Vedo... Docetaxel Vinflunine Paclitaxel | 18 Years - | Astellas Pharma Inc | |
| A Study of the Interaction of Rifampin and Vinflunine in Subjects With Advanced Cancer | NCT00534807 | Cancer | Vinflunine Rifampin | 18 Years - | Bristol-Myers Squibb | |
| Ph II of Vinflunine and Cetuximab in Second Line Treatment of NSCLC | NCT00519831 | Lung Cancer | cetuximab vinflunine | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| A Phase II Single Arm Trial of Single-agent Vinflunine as Second-line Treatment of Advanced Non-Small Cell Lung Cancer | NCT00251446 | Non-Small Cell ... | Vinflunine | 18 Years - | Veeda Oncology | |
| First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy | NCT00389155 | Bladder Cancer Transitional Ce... Metastasis | Vinflunine Gemcitabine Placebo | 18 Years - | Bristol-Myers Squibb | |
| First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy | NCT00389155 | Bladder Cancer Transitional Ce... Metastasis | Vinflunine Gemcitabine Placebo | 18 Years - | Bristol-Myers Squibb | |
| Cabazitaxel vs. Vinflunine in Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium (TCCU) | NCT01830231 | Urothelium Tran... | Cabazitaxel Vinflunine | 18 Years - | Associació per a la Recerca Oncologica, Spain | |
| A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations | NCT03390504 | Urothelial Canc... | Erdafitinib Vinflunine Docetaxel Pembrolizumab Fibroblast Grow... | 18 Years - | Janssen Research & Development, LLC | |
| A Phase II Single Arm Trial of Single-agent Vinflunine as Second-line Treatment of Advanced Non-Small Cell Lung Cancer | NCT00251446 | Non-Small Cell ... | Vinflunine | 18 Years - | Veeda Oncology | |
| Phase III Study of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer | NCT01953003 | Malignant Neopl... | vinflunine Capecitabine | 21 Years - 80 Years | Pierre Fabre Medicament | |
| Vinflunine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2neu) Over-Expressing Metastatic Breast Cancer | NCT00284180 | Breast Neoplasm... Breast Cancer | Vinflunine Trastuzumab | 18 Years - | SCRI Development Innovations, LLC | |
| JAVLOR Association Study in CDDP-unfit Patients With Advanced Transitional Cell Carcinoma: Gemcitabine Versus Carboplatin | NCT01599013 | Bladder Transit... | Vinflunine, Gem... Vinflunine, Car... | 18 Years - 79 Years | Pierre Fabre Medicament | |
| Clinical Trial With Vinflunine as Maintenance Therapy in Metastatic Urothelial Cancer | NCT01529411 | Carcinoma, Tran... | Vinflunine Undefined (stan... | 18 Years - 80 Years | Spanish Oncology Genito-Urinary Group | |
| JAVLOR Association Study in CDDP-unfit Patients With Advanced Transitional Cell Carcinoma: Gemcitabine Versus Carboplatin | NCT01599013 | Bladder Transit... | Vinflunine, Gem... Vinflunine, Car... | 18 Years - 79 Years | Pierre Fabre Medicament | |
| A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045) | NCT02256436 | Urothelial Canc... | pembrolizumab paclitaxel vinflunine docetaxel | 18 Years - | Merck Sharp & Dohme LLC | |
| Vinflunine and Erlotinib or Pemetrexed in Treating Patients With Unresectable or Metastatic Solid Tumors | NCT00320073 | Unspecified Adu... | erlotinib hydro... pemetrexed diso... vinflunine | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations | NCT03390504 | Urothelial Canc... | Erdafitinib Vinflunine Docetaxel Pembrolizumab Fibroblast Grow... | 18 Years - | Janssen Research & Development, LLC | |
| Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract | NCT01844947 | Urothelial Carc... Bladder Cancer Renal Pelvis Ca... Ureter Cancer Urethra Cancer | Vinflunine Sorafenib | 18 Years - 80 Years | Karolinska University Hospital | |
| Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium | NCT00101608 | Transitional Ce... Bladder Neoplas... Kidney Neoplasm... Ureter Neoplasm... Bladder Cancer Neoplasm, Bladd... | vinflunine | 18 Years - | Bristol-Myers Squibb | |
| A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045) | NCT02256436 | Urothelial Canc... | pembrolizumab paclitaxel vinflunine docetaxel | 18 Years - | Merck Sharp & Dohme LLC | |
| Vinflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung Cancer | NCT00284154 | Carcinoma, Smal... Lung Cancer | Vinflunine | 18 Years - | SCRI Development Innovations, LLC | |
| Clinical Trial With Vinflunine as Maintenance Therapy in Metastatic Urothelial Cancer | NCT01529411 | Carcinoma, Tran... | Vinflunine Undefined (stan... | 18 Years - 80 Years | Spanish Oncology Genito-Urinary Group | |
| Phase III Study of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer | NCT01953003 | Malignant Neopl... | vinflunine Capecitabine | 21 Years - 80 Years | Pierre Fabre Medicament | |
| Vinflunine and Capecitabine in Treating Patients With Previously Treated Metastatic Breast Cancer | NCT00450515 | Breast Cancer | capecitabine vinflunine | 18 Years - | Alliance for Clinical Trials in Oncology | |
| A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal Function | NCT02665039 | Urothelial Carc... Bladder Cancer Renal Pelvis Ca... Ureter Cancer Urethra Cancer | Vinflunine Gemcitabine Carboplatin | 18 Years - | Karolinska University Hospital | |
| A Phase II Single Arm Trial of Single-agent Vinflunine as Second-line Treatment of Advanced Non-Small Cell Lung Cancer | NCT00251446 | Non-Small Cell ... | Vinflunine | 18 Years - | Veeda Oncology | |
| A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal Function | NCT02665039 | Urothelial Carc... Bladder Cancer Renal Pelvis Ca... Ureter Cancer Urethra Cancer | Vinflunine Gemcitabine Carboplatin | 18 Years - | Karolinska University Hospital | |
| Phase Ib/II Study Assessing the Neo-adjuvant Combination Therapy of Vinflunine With Cisplatin Followed by Radical Cystectomy in Patients With Muscle-invasive Bladder Cancer (JaNEO) | NCT02845050 | Bladder Cancer | Vinflunine Cisplatin Radical cystect... | 18 Years - 75 Years | Ligartis GmbH | |
| Vinflunine and Erlotinib or Pemetrexed in Treating Patients With Unresectable or Metastatic Solid Tumors | NCT00320073 | Unspecified Adu... | erlotinib hydro... pemetrexed diso... vinflunine | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations | NCT03390504 | Urothelial Canc... | Erdafitinib Vinflunine Docetaxel Pembrolizumab Fibroblast Grow... | 18 Years - | Janssen Research & Development, LLC | |
| Vinflunine in Hormone Refractory Prostate Cancer (HRPC) | NCT00545766 | Prostate Cancer | Vinflunine | 18 Years - | SCRI Development Innovations, LLC | |
| A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations | NCT03390504 | Urothelial Canc... | Erdafitinib Vinflunine Docetaxel Pembrolizumab Fibroblast Grow... | 18 Years - | Janssen Research & Development, LLC | |
| Vinflunine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2neu) Over-Expressing Metastatic Breast Cancer | NCT00284180 | Breast Neoplasm... Breast Cancer | Vinflunine Trastuzumab | 18 Years - | SCRI Development Innovations, LLC | |
| Study of Sacituzumab Govitecan-hziy (IMMU-132) Versus Treatment of Physician's Choice in Participants With Metastatic or Locally Advanced Unresectable Urothelial Cancer | NCT04527991 | Locally Advance... | Sacituzumab Gov... Paclitaxel Docetaxel Vinflunine | 18 Years - | Gilead Sciences | |
| A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211] | NCT02302807 | Bladder Cancer | Atezolizumab (M... Docetaxel Paclitaxel Vinflunine | 18 Years - | Hoffmann-La Roche |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
